Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron plus biofeedback for overactive bladder in women
IRCT20230629058615N11Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mirabegron in overactive bladder (OAB) (2 arms), sponsored by Iran University of Medical Sciences. Primary endpoints: Severity of overactive bladder symptoms and Quality of life associated with overactive bladder syndrome. Started Mar 2026; status: completed.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on IRCT20230629058615N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230629058615N11.